Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Poseida, Legend/Janssen Look To Snag Celgene/Bluebird's BCMA Crown

Executive Summary

Poseida and Legend/Janssen aim to develop CAR-T therapies with improved efficacy and safety, and both programs delivered updates at ASH for BCMA-targeting CAR-T candidates in multiple myeloma that could challenge Celgene/bluebird's lead in this field.

Advertisement

Related Content

Keeping Track: Yupelri Is Latest Novel Drug Approved, But Bad News For Biosimilars
China CAR-T Front-Runner Allegations Reveal Soft Underbelly Of Development Race
Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year
Celgene Seeks CAR-T Leadership, Hematology Diversification With Juno Buy
China Looms Large Seeking New Funding, Deals At J.P. Morgan
Celgene's CAR-T Leadership Goals Advance At ASH 2017

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124274

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel